Acrux investors have taken heart from a ruling by the European drug regulator that testosterone therapy does not increase the risk of cardiac problems.
Acrux investors have taken heart from a ruling by the European drug regulator that testosterone therapy does not increase the risk of cardiac problems.
The biotechnology stock surged 24 per cent to $1.28 on Friday after the European Medicines Agency memo.
Loading...
Jessica Gardner is Deputy editor - News. She has previously edited the Companies and Markets section. Connect with Jessica on Twitter. Email Jessica at jgardner@afr.com
